

We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
![]() | Indaptus Therapeutics Inc | 0.5831 | 0.313 | 115.88% | 64,165,524 |
![]() | Cidara Therapeutics Inc | 37.50 | 16.48 | 78.40% | 343,030 |
![]() | OceanPal Inc | 2.33 | 0.89 | 61.81% | 9,980,336 |
![]() | Huachen AI Parking Management Technology Holding Company Ltd | 1.33 | 0.3479 | 35.42% | 13,325,226 |
![]() | DIH Holdings US Inc | 0.2893 | 0.0683 | 30.90% | 25,889,913 |
![]() | Robin Energy Ltd | 7.95 | 1.83 | 29.90% | 2,830,399 |
![]() | Leap Therapeutics Inc | 0.48 | 0.103 | 27.32% | 15,633,752 |
![]() | Exelixis Inc | 50.71 | 10.34 | 25.61% | 90,726 |
![]() | Forte Biosciences Inc | 17.75 | 3.09 | 21.08% | 3,430 |
![]() | Fortress Biotech Inc | 2.15 | 0.37 | 20.79% | 804 |
![]() | US Energy Corp | 2.12 | 0.36 | 20.45% | 1,641,448 |
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint is the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the active treatment group and the placebo group at week 6. A single dose of COMP360 25 mg versus placebo demonstrated a highly statistically significant reduction in symptom severity with ...
Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without ...
Marin Software Incorporated (NASDAQ: MRIN) (“Marin,” “we,” “our,” or the “Company”), a provider of digital marketing software for performance-driven advertisers and agencies, announces that, on June 17, 2025, the Company received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that Nasdaq had determined that the Company did not provide a definitive plan evidencing its ability to achieve compliance with the Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”). The Company had previously submitted ...
Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
TWOH | Two Hands Corp | ||
DTREF | Dateline Resources Ltd | ||
COOP | Mr Cooper Group Inc | ||
4 | AMRN | Amarin Corp Plc | |
5 | XRPUSD | Ripple | |
6 | AZRH | Azure Holding Group Corp |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
![]() | Bitcoin | 101,280.92 | 275.03 | 0.27% | 2.01T | 5,540,088,339 |
![]() | Ethereum | 2,251.14 | 22.54 | 1.01% | 270.86B | 3,501,804,211 |
![]() | Tether USD | 1.00 | 0.00 | 0.00% | 141.93B | 80,725,294 |
![]() | Ripple | 2.00 | -0.020 | -0.99% | 115.53B | 994,193,492 |
![]() | Binance Coin | 616.63 | 0.388238 | 0.06% | 97.5B | 178,290,403 |
![]() | Solana | 134.02 | 2.30 | 1.75% | 65.21B | 1,060,501,582 |
![]() | USD Coin | 0.9998 | 0.00 | 0.00% | 56.09B | 1,538,819,742 |
![]() | TRON | 0.266789 | 0.003277 | 1.24% | 23B | 279,416,404 |
![]() | Dogecoin | 0.1516 | 0.00025 | 0.17% | 22.43B | 551,232,773 |
![]() | stETH | 2,249.71 | 23.12 | 1.04% | 21.09B | 3,498,823 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions